Close Menu

NEW YORK – While recent actions by the federal government directed at nursing homes could increase the need for SARS-CoV-2 tests to nearly unheard-of volumes, the industry said it is ready and will meet the anticipated demand.

Specifically, the developers and manufacturers of rapid antigen tests for the coronavirus said that they are prepared for what could be an enormous demand for such tests, which detect protein antigens, rather than viral antigens as with PCR-based tests. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.